Lovastatin
Hmg Coa Reductase Inhibitors
- Drug class
- Hmg Coa Reductase Inhibitors
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 2
- Products on record
- 9
- FDA reports (12 mo)
- 471
Overview
Plain-language summary, compiled from the cited regulatory records
Lovastatin is a medication belonging to the drug class of HMG-CoA reductase inhibitors [1]. It is approved for use as part of a comprehensive intervention strategy for individuals with dyslipidemia who are at risk for atherosclerotic vascular disease [1]. Lovastatin is intended to be used in conjunction with a diet low in saturated fat and cholesterol to help lower total cholesterol and LDL cholesterol levels when diet and other non-pharmacological measures alone are insufficient to manage risk [1].
In the past 12 months, there have been 471 adverse event reports associated with lovastatin [2]. Common adverse reactions reported include fatigue, diarrhea, dizziness, and issues related to product dose omission or the drug being ineffective [2]. Lovastatin is available under various brand names [1].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 7 | May 29, 2026 |
| CA Canada | Health Canada | 2 | August 15, 2025 |
USUnited States· FDA
7 products
Uses
INDICATIONS AND USAGE
Therapy with Lovastatin Tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin Tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk.
) Coronary Heart Disease Lovastatin Tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia.
CACanada· Health Canada
2 products
2 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [2].
Drug interactions
Known interactions involving Lovastatin. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 503. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 027bd594-6a0a-4e… · revised April 1, 2020 [PDF]
- [2]Health Canada (DPD) · 02220172 · revised August 15, 2025
- [3]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.